SeaBOS aims to minimise antibiotics use by improving overall health management in aquaculture, adopting preventative practices, and implementing a Code of Conduct for responsible antibiotics use. Through data collection, enhanced farm management practices, disease diagnostics, and the development of preventative strategies and resources like vaccines, we strive to promote transparency and accountability. We work collaboratively with diverse stakeholders, including pharmaceutical companies, veterinarians, intergovernmental agencies, and government departments, to develop and improve stewardship and alternatives to antibiotics.
Antibiotic use has contributed to the spread of antimicrobial resistance, an emerging public health crisis estimated by the United Nations to result in up to 10 million deaths annually by 2050. While antibiotics enable greater food production and have importance for animal welfare, considerable scope exists to limit usage by reducing misuse and over-application around the world. Over longer timeframes, the development of vaccines can reduce dependency on antibiotics; in Norway, for instance, vaccines have resulted in the virtual elimination of antibiotics in salmon aquaculture production. Over 600 species are in aquaculture production around the world, but vast gaps exist in knowledge about the quantity and type of antibiotics used in these diverse production systems, hampering action and progress.
The improper use of antibiotics in aquaculture results in the loss of efficacy of antimicrobials crucial for human healthcare. Focusing on reducing and eventually eliminating the need for Critically Important Antimicrobials for Human Medicine, as identified by the World Health Organization is a crucial priority. A focus on responsible antibiotic use and overall health management is indispensable to ensure the sustainable future of the aquaculture industry. Companies can contribute by providing transparent accessibility of data, engaging in vaccine development, and contributing to eliminating vast knowledge gaps about the frequency and prevalence of antimicrobial resistant genes in production systems around the world.
Nissui, Maruha Nichiro and Kyokuyo are working together with Japanese government offices and the pharmaceutical industry in Japan to reduce antibiotics use and develop vaccines that enable a transfer away from the use of highest priority critically important antibiotics (HPCIA).
The SeaBOS Antibiotics Code of Conduct provides strategies for maintaining fish health and welfare
and reducing use of antibiotics through preventative practices and interventions. Furthermore, the SeaBOS Antibiotic Stewardship Roadmap guides members in the phasing out of HPCIA and CIA in line with World Health Organization (WHO) standards.